PGC1α alleviates M1 macrophage polarization through dual regulation of succinate metabolism and TRAF5 expression to mitigate TLR4/NF-κB-driven inflammatory cascades and myocardial ischemia/reperfusion injury
- 6 November 2025
- journal article
- research article
- Published by Springer Nature in Inflammation Research
- Vol. 74 (1) , 1-22
Abstract
Objective This study investigates the dual regulatory role of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) in macrophage polarization and its therapeutic potential for mitigating myocardial ischemia/reperfusion injury (MI/RI). Methods By integrating in vivo murine myocardial MI/RI models with macrophage-specific genetic manipulation and multi-omics analyses, including transcriptomics, proteomics, and energy metabolomics, we comprehensively investigated the cardio-protective effects, immune regulation, and potential mechanism of PGC1α. Mechanistic validations were performed using macrophage hypoxia/reoxygenation models combined with gain- and loss-of-function experiments to elucidate the molecular interactions within the PGC1α-mediated signaling network. Results PGC1α emerged as a potential regulator of macrophage polarization through coordinated metabolic and protein regulation in MI/RI. It suppresses TLR4/NF-κB-driven inflammation via two prominent parallel pathways: (1) Metabolic control through SUCLG1/succinyl-CoA synthetase-mediated succinate generation; (2) negatively regulates protein by TRAF5 mRNA expression inhibition. This dual-axis regulation effectively dampens M1 macrophage polarization and pro-inflammatory cytokine storms. Furthermore, macrophage-specific PGC1α activation demonstrated cardio-protective effects by preserving cardiac function and reducing cardiomyocyte apoptosis. Conclusion Our findings established PGC1α as a potential regulator of macrophage polarization in MI/RI, bridging mitochondrial energy metabolism and protein expression with immune responses. The PGC1α-SUCLG1/succinate axis and PGC1α-TRAF5 axis unveil therapeutic targets and potential mechanisms for modulating inflammation in MI/RI. Future studies should focus on translating these mechanisms into clinical interventions through pharmacological PGC1α activation.Keywords
This publication has 44 references indexed in Scilit:
- Exosomes generated from bone marrow mesenchymal stem cells limit the damage caused by myocardial ischemia-reperfusion via controlling the AMPK/PGC-1α signaling pathwayBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2025
- ROS Responsive Cerium Oxide Biomimetic Nanoparticles Alleviates Calcium Oxalate Crystals Induced Kidney Injury via Suppressing Oxidative Stress and M1 Macrophage PolarizationSmall, 2024
- Sirtuin1 Suppresses Calcium Oxalate Nephropathy via Inhibition of Renal Proximal Tubular Cell Ferroptosis Through PGC‐1α‐mediated Transcriptional CoactivationAdvanced Science, 2024
- Advances in macrophage metabolic reprogramming in myocardial ischemia-reperfusionCellular Signalling, 2024
- Rosiglitazone attenuates Acute Kidney Injury from hepatic ischemia–reperfusion in mice by inhibiting arachidonic acid metabolism through the PPAR-γ/NF-κB pathwayInflammation Research, 2024
- Emerging insights into the pathogenesis and therapeutic strategies for vascular endothelial injury-associated diseases: focus on mitochondrial dysfunctionAngiogenesis, 2024
- Ceria Nanoparticles as Copper Chaperones that Activate SOD1 for Synergistic Antioxidant Therapy to Treat Ischemic Vascular DiseasesAdvanced Materials, 2023
- Cardiac-specific overexpression of Claudin-5 exerts protection against myocardial ischemia and reperfusion injuryBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2022
- Mechanism of TLR-4/NF-κB pathway in myocardial ischemia reperfusion injury of mouseAsian Pacific Journal of Tropical Medicine, 2016
- Recombinant Human Interleukin-1 Receptor Antagonist Provides Cardioprotection During Myocardial Ischemia Reperfusion in the MouseCardiovascular Drugs and Therapy, 2012